OTX-TKI (axitinib implant)

Phase 3

OCULAR THERAPEUTIX, INC (OCUL)

55%

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

Upcoming Catalysts

Apr 29

OCUL⭐Phase 3Phase 3

OTX-TKI (axitinib implant) Phase 3 Results Expected

OTX-TKI (axitinib implant) • Neovascular Age-Related Macular Degeneration

Drug Information

Target Indication

Neovascular Age-Related Macular Degeneration

Clinical Trial

NCT06223958

Last updated: 12/4/2025

Regulatory Approvals

EMA9/2/2012

Inlyta

Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.

View on EMA

Developer

OCUL

OCULAR THERAPEUTIX, INC

Biotechnology•North America•NASDAQ